Welcome

Influenza-Like Illness (ILI) Management Malaysia – KKM Guide

SETELDOC CLINICAL REFERENCE • MALAYSIA

Influenza-Like Illness (ILI) Management in Malaysia

A practical primary care guide covering the KKM influenza management pathway, risk assessment, oseltamivir treatment doses, hospital referral criteria, pregnancy and newborn care.

Based on the KKM 2023 influenza guideline and Malaysian National Antimicrobial Guideline (NAG) 2024 online edition. References checked: 14 November 2026.

What is influenza-like illness (ILI)?

The Malaysian Ministry of Health (KKM) defines ILI for its general assessment pathway as a history of fever ≥38°C and cough, with onset within the preceding 10 days. It is a clinical syndrome, not proof of influenza-virus infection. Consider other causes of acute fever and respiratory symptoms, including dengue and COVID-19 when clinically relevant.

Pregnancy-specific exception: the KKM pregnancy pathway recognises fever that may not exceed 38°C, with cough and/or sore throat, within seven days of symptom onset. Do not exclude a pregnant patient solely because the measured temperature is below 38°C.

ILI management algorithm for primary care

Triage by illness severity first. Then assess comorbidities and risk factors.

PATHWAY 01

Moderate or severe ILI

Refer for hospital assessment. Evaluate respiratory distress, oxygenation, hydration, circulation and mental status. Escalate urgently if unstable.

PATHWAY 02

Mild ILI without risk factors

Offer symptomatic treatment, adequate fluids, rest, infection-control advice and a clear home assessment or safety-net plan.

PATHWAY 03

Mild ILI with risk factors

Assess for early oseltamivir treatment and arrange home care with explicit return precautions. Reassess if clinical status worsens.

Antiviral decisions should be based on clinical suspicion, symptom onset, severity and patient risk. When treatment is indicated, KKM advises not to delay solely while awaiting laboratory results.

Who is at increased risk of influenza complications?

Adults — KKM risk factors

  1. Chronic respiratory disease, including asthma, COPD or obstructive sleep apnoea.
  2. Pregnancy and up to two weeks postpartum.
  3. Morbid obesity: BMI ≥40 kg/m².
  4. Chronic cardiac disease (excluding uncomplicated hypertension), diabetes mellitus, renal failure, haemoglobinopathies or immunosuppression, including malignancy, HIV, chemotherapy and long-term corticosteroids.
  5. Age ≥65 years, particularly with other chronic conditions.

Paediatric — KKM risk factors

  1. Cardiac disease.
  2. Chronic respiratory disease, such as asthma or bronchopulmonary dysplasia.
  3. Other chronic illnesses, including diabetes, metabolic disease, renal failure and haemoglobinopathies.
  4. Chronic neurological disorders, such as muscular dystrophy.
  5. Impaired immunity, malignancy or immunosuppressive therapy.
  6. Malnutrition or obesity.

Age criterion clarification: the paediatric KKM list prints “Children aged 6 months” without stating whether it means below, at or another age range. This wording is ambiguous in the source document, so no specific age threshold is inferred here. Assess younger infants carefully using current paediatric protocols.

Oseltamivir treatment dosing in Malaysia

The following paediatric regimen follows the online Malaysian National Antimicrobial Guideline (NAG) 2024. Doses are oral, given twice daily (BD) for five days. This is treatment dosing, not post-exposure prophylaxis dosing.

Infants below 12 months

Age Oseltamivir treatment dose
Below 9 months 3 mg/kg/dose BD
9–11 months 3.5 mg/kg/dose BD

Children aged 1–12 years

Body weight Oseltamivir treatment dose
≤15 kg 30 mg BD
>15–23 kg 45 mg BD
>23–40 kg 60 mg BD
>40 kg 75 mg BD

Adults

75 mg orally BD for 5 days is the usual adult treatment regimen for patients with appropriate renal function.

When to start

Greatest benefit is expected when oseltamivir begins within 48 hours of symptom onset. KKM allows later initiation on an individual basis for selected high-risk patients; do not assume that presentation after 48 hours always excludes treatment.

Prescribing checks

Confirm indication, age, current weight, renal function, formulation strength and current references before prescribing. Renal dose adjustment may be needed. Use a verified preparation-specific calculation when dispensing suspension.

Source distinction: the infant dosing table in the 2023 KKM PDF differs from the subsequently published online NAG regimen above. This page deliberately follows NAG for paediatric doses and identifies that source transparently.

Useful SetelDoc references: Oseltamivir dose calculator and Tamiflu renal dose reference.

When should an ILI patient be referred to hospital?

KKM recommends hospital assessment for moderate or severe illness. Referral decisions should reflect the full clinical assessment, not a single measurement.

Respiratory red flags

  • Respiratory distress or accessory muscle use.
  • Tachypnoea, respiratory exhaustion or inability to complete a sentence.
  • Hypoxaemia or worsening oxygenation.
  • Chest pain or rapidly worsening respiratory symptoms.

Other red flags

  • Clinical dehydration or shock.
  • Confusion, altered consciousness or seizures.
  • Severe or persistent vomiting, inability to maintain hydration.
  • Rapid clinical deterioration, severe atypical presentation or significant lethargy or feeding difficulty in children.
Oxygen saturation: KKM’s general adult and paediatric assessment tools include SpO₂ ≤95% among indicators for consideration of hospital admission. Its separate pregnancy-specific tool lists SpO₂ ≤92%. Neither threshold should replace clinical assessment or be interpreted as reassurance above the stated value.

Home care and safety-net advice

Care at home when clinically suitable

  • Rest and maintain fluid intake.
  • Use paracetamol at an appropriate dose when fever causes discomfort.
  • Practise hand hygiene, cough etiquette and ventilation.
  • Wear a mask when symptomatic around other people and reduce close contact.

Return urgently if

  • Breathlessness, fast breathing, persistent chest pain or blue lips occur.
  • Fever lasts more than three days or returns after three days.
  • Confusion, seizures, reduced responsiveness or marked drowsiness develop.
  • Persistent vomiting or diarrhoea, poor intake or reduced urine output occurs.

ILI management in pregnancy

Pregnancy is an important risk factor for influenza complications. The KKM 2023 pregnancy pathway applies a broader clinical case assessment than the general ILI case definition.

Mild illness in pregnancy

  • Assess promptly in a designated area.
  • KKM recommends a five-day oseltamivir course for pregnant patients meeting its ILI pathway.
  • Provide symptomatic care, infection-control guidance and danger-sign advice.
  • Routine throat swabbing is not required in the pathway.
  • Rearrange routine antenatal visits if clinically safe to avoid exposure to other mothers; never delay necessary obstetric care.

Refer or admit to hospital

  • Moderate or severe illness.
  • Significant obstetric or medical complications.
  • Serious atypical presentation or rapid deterioration.

Maintain a low threshold for reassessment when clinical concerns arise.

Newborn care when the mother has ILI

Breastfeeding and prevention

  • Continue breastfeeding; maternal oseltamivir is not a contraindication.
  • Wash hands and wear a surgical mask when feeding or handling the baby.
  • If feasible, a healthy caregiver can provide expressed breast milk during the mother’s symptomatic period.
  • Reduce close exposure while protecting feeding and mother–baby care.

Newborn danger signs

Seek urgent hospital assessment for any fever, poor feeding, reduced urine output, unusual lethargy, fast or difficult breathing, seizures or pallor/cyanosis.

Frequently asked questions

What is the KKM definition of influenza-like illness?

In the general KKM 2023 ILI pathway, fever ≥38°C and cough with symptom onset within 10 days. The separate pregnancy pathway recognises fever below 38°C with cough and/or sore throat.

Does every ILI patient need oseltamivir?

No. Mild illness without significant risk factors is usually managed symptomatically. Antiviral treatment is considered for patients with relevant risk factors or other clinical indications; suspected moderate or severe illness needs hospital assessment.

How soon should oseltamivir be started?

Ideally within 48 hours of symptom onset. The Malaysian KKM guidance allows case-by-case initiation after 48 hours in selected high-risk patients.

What is the usual adult oseltamivir treatment dose?

75 mg orally twice daily for five days in patients with appropriate renal function. Check renal adjustment where indicated.

Can oseltamivir be used in pregnancy and during breastfeeding?

KKM recommends oseltamivir treatment for pregnant patients meeting its ILI pathway, including clinically mild cases. Breastfeeding is not contraindicated while taking oseltamivir.

What is the SpO₂ threshold in the KKM influenza guideline?

General adult and paediatric assessment tools list SpO₂ ≤95% as a factor supporting consideration of hospital admission. The pregnancy-specific assessment tool separately lists ≤92%. All cases require overall clinical judgment.

Need a paediatric dose calculator during GP or locum?

Explore SetelDoc’s free trial to calculate common paediatric clinic doses and review prescribing information. No credit card required.

Try SetelDoc Dose Calculator

References and clinical disclaimer

  1. Ministry of Health Malaysia. Garispanduan Pengendalian Influenza di Klinik Kesihatan. Pindaan 7 Ogos 2023 (PDF). Clinical pathways, risk factors, referral criteria, pregnancy and newborn care.
  2. Ministry of Health Malaysia. National Antimicrobial Guideline 2024, online paediatric respiratory infections chapter. Paediatric oseltamivir treatment doses.
  3. KKM Formulary of Medicines: Oseltamivir. Local indications, adult dose and renal caution.

For healthcare professional education only. This independent SetelDoc summary is not an official KKM publication or a substitute for a full clinical assessment, current local protocols, prescribing information or specialist advice. Verify original guidance, medicine formulation and individual patient suitability before clinical use. The source documents may be updated.

SetelDoc

Top
VIP
Login | Out
Help
Scroll to Top